

*In the claims:*

1. – 20. (Cancelled)

21. (Currently Amended) An immunogenic composition comprising at least one peptide which is an amino acid sequence subunit of glucosyltransferase of 15 - 22 ~~24~~ amino acids in length comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; and SEQ ID NO: 19.

22. (Original) An immunogenic composition comprising at least one peptide consisting essentially of SEQ ID NO: 3.

23. (Currently Amended) ~~The~~ An immunogenic composition according to Claim 21 wherein ~~2 or more peptides are present and arranged on~~ comprising a macromolecular structure, said structure comprising a peptidyl core matrix comprising at least one amino acid selected from the group consisting of 3 or more a ~~lysines, arginine, and histidine residue; and at least two glucosyltransferase polypeptides covalently attached to said peptidyl core amino acid, wherein said glucosyltransferase polypeptides are selected from the group consisting of~~ SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; and SEQ ID NO: 19.

APPLICANTS: Smith and Taubman  
SERIAL NUMBER: 09/290,049

24. - 80. (Cancelled)

81. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 1.

82. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 2.

83. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 10.

84. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 11.

85. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 12.

86. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 13.

87. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 14.

88. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 15.

89. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 16.

APPLICANTS: Smith and Taubman  
SERIAL NUMBER: 09/290,049

90. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 17.

91. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 18.

92. (Previously Added) The immunogenic composition of Claim 21, wherein said amino acid sequence is SEQ ID NO: 19.

93. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 1 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

94. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 2 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

95. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 10 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

96. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 11 and an amino acid

APPLICANTS: Smith and Taubman  
SERIAL NUMBER: 09/290,049

sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

97. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 12 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

98. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 13 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

99. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 14 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

100. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 15 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

101. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 16 and an amino acid

sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

102. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 17 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

103. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 18 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

104. (Currently Amended) The immunogenic composition of Claim 2523, wherein said at least two peptides is an amino acid sequence of SEQ ID NO: 19 and an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 10, 11, 12, 13, 14, 15, 16, 17, 18, and 19.

105. (Currently Amended) ~~The An~~ immunogenic composition of Claim 22, wherein ~~2 or more comprising a radially branched macromolecular structure, said structure comprising peptides are present and arranged on a peptidyl core matrix of comprising at least 3 or more amino acids selected from the group consisting of a lysines, arginine, and histidine residue; and at least 4 glucosyltransferase polypeptides, each polypeptide of which is covalently attached to and radially branched about said peptidyl core amino acid, wherein said glucosyltransferase polypeptides are selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO:~~

APPLICANTS: Smith and Taubman

SERIAL NUMBER: 09/290,049

13; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18;

and SEQ ID NO: 19.